Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Sugammadex Reversal of Rocuronium in Children
NCT03943888Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2019
- Primary completion
- Feb 2020
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Sugammadex in neuromuscular blockade (NMB) (4 arms), sponsored by Seoul National University Hospital. Primary endpoint: Time to Neuromuscular Recovery at 1 hour. Started Aug 2019; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03943888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943888.